# Summary of Consolidated Financial Results for the Year Ended September 30, 2019 <br> (Based on Japanese GAAP) 

November 8, 2019
Company name: Fuji Pharma Co., Ltd.
Stock exchange listing: Tokyo
Stock code: 4554 URL http://www.fujipharma.jp
Representative: Chairman and Representative Director Hirofumi Imai Director, Executive Corporate

Inquiries:
Officer,General Manager, Corporate Business Management Department
Scheduled date of ordinary general meeting of shareholders:
Scheduled date to file Securities Report:
Scheduled date to commence dividend payments:
Preparation of supplementary material on financial results:
Holding of financial results meeting:

Toyoyuki Kamide
TEL 03-3556-3344

December 19, 2019
December 19, 2019
December 20, 2019
Yes
Yes (for institutional investors and analysts)
(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the year ended September 30, 2019 (from October 1, 2018 to September 30, 2019)
(1) Consolidated operating results

Percentages indicate year-on-year changes

|  | Net sales |  | Operating profit |  | Ordinary profit |  | Profit attributable to <br> owners of parent |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Millions of yen | $\%$ | Millions of yen | $\%$ | Millions of yen | $\%$ | Millions of yen | $\%$ |
| Year ended September 30, 2019 | 36,279 | $(4.3)$ | 4,173 | $(5.0)$ | 4,169 | $(6.8)$ | 2,962 | $(12.2)$ |
| Year ended September 30, 2018 | 37,909 | 7.1 | 4,391 | 1.8 | 4,472 | $(3.4)$ | 3,372 | 2.2 |


|  | Earnings per share | Diluted earnings per <br> share | Profit attributable to <br> owners of <br> parent/equity | Ordinary profit/total <br> assets | Operating profit/net <br> sales |
| :--- | ---: | ---: | ---: | ---: | ---: |
|  | Yen | 97.04 | Yen | $\%$ | $\%$ |
| Year ended September 30,2019 | 112.68 | - | 7.9 | 7.3 | 11.5 |
| Year ended September 30,2018 | - | 9.9 | 8.7 | 11.6 |  |

(2) Consolidated financial position

|  | Total assets | Net assets | Equity ratio | Net assets per share |
| :--- | ---: | ---: | ---: | ---: |
|  | Millions of yen | Millions of yen | $\%$ | Yen |
| As of September 30, 2019 | 60,737 | 39,363 | 64.8 | $1,263.51$ |
| As of September 30, 2018 | 53,117 | 35,350 | 66.5 | $1,181.37$ |

(3) Consolidated cash flows

|  | Cash flows from <br> operating activities | Cash flows from <br> investing activities | Cash flows from <br> financing activities | Cash and cash equivalents <br> at end of period |
| :--- | ---: | ---: | ---: | ---: |
|  | Millions of yen | Millions of yen | Millions of yen | Millions of yen <br> Year ended September 30, 2019 |
| Year ended September 30, 2018 | 7,035 | $(12,024)$ | 8,265 | $(2,001)$ |

2. Cash dividends

|  | Annual dividends per share |  |  |  |  | Total cashdividends (Total) | Dividend payout <br> ratio (Consolidated | Ratio of dividends (Consolidated) (Consolidated) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1st quarter-end | 2nd quarter-end | 3rd quarter-end | Fiscal year-end | Total |  |  |  |
|  | Yen | Yen | Yen | Yen | Yen | Millions of yen | \% | \% |
| Year ended September 30, 2018 | - | 28.00 | - | 14.00 | - | 839 | 24.9 | 2.5 |
| Year ended September 30, 2019 | - | 14.00 | - | 15.00 | 29.00 | 887 | 29.9 | 2.4 |
| Year ending September 30, 2020 (Forecast) | - | 14.00 | - | 15.00 | 29.00 |  | 54.3 |  |

3. Forecast of consolidated financial results for the year ending September 30, 2020 (from October 1, 2019 to September 30, 2020)

Percentages indicate year-on-year changes

|  | Net sales |  | Operating profit |  | Ordinary profit |  | Profit attributable to owners of parent |  | Earnings per share |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | Yen |
| Six months ending March 31, 2020 | 16,647 | (9.9) | 1,209 | (51.0) | 1,174 | (53.1) | 781 | (53.9) | 25.09 |
| Full year | 33,830 | (6.8) | 2,571 | (38.4) | 2,501 | (40.0) | 1,664 | (43.8) | 53.44 |

4. Notes
(1) Changes in significant subsidiaries during the year ended September 30, 2019
(changes in specified subsidiaries resulting in the change in scope of consolidation):
(2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements

Changes in accounting policies due to revisions to accounting standards and other regulations: No
Changes in accounting policies due to other reasons: No
Changes in accounting estimates: No
Restatement of prior period financial statements: No
(3) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

| As of September 30, 2019 | $31,253,800$ shares | As of September 30, 2018 | $31,253,800$ shares |
| :--- | :--- | :--- | :--- |

Number of treasury shares at the end of the period

| As of September 30, 2019 | 101,726 shares | As of September 30, 2018 | 1 | $1,332,442$ shares |
| :--- | :--- | :--- | :--- | :--- |

Average number of shares during the period

| Year ended September 30, 2019 | 30,528,634 shares | Year ended September 30, 2018 | 29,928,670 shares |
| :--- | :--- | :--- | :--- |

## Consolidated financial statements

Consolidated balance sheets

|  | (Millions of yen) |  |
| :---: | :---: | :---: |
|  | As of September 30, 2018 | As of September 30, 2019 |
| Assets |  |  |
| Current assets |  |  |
| Cash and deposits | 6,251 | 8,494 |
| Notes and accounts receivable - trade | 16,903 | 12,944 |
| Merchandise and finished goods | 3,169 | 3,437 |
| Work in process | 2,812 | 2,539 |
| Raw materials and supplies | 5,303 | 4,735 |
| Accounts receivable - other | 39 | 43 |
| Other | 453 | 1,724 |
| Allowance for doubtful accounts | (6) | (0) |
| Total current assets | 34,927 | 33,919 |
| Non-current assets |  |  |
| Property, plant and equipment |  |  |
| Buildings and structures | 11,023 | 10,888 |
| Accumulated depreciation | $(5,449)$ | $(5,770)$ |
| Buildings and structures, net | 5,573 | 5,117 |
| Machinery, equipment and vehicles | 9,078 | 8,596 |
| Accumulated depreciation | $(7,263)$ | $(6,950)$ |
| Machinery, equipment and vehicles, net | 1,814 | 1,646 |
| Land | 915 | 919 |
| Leased assets | 4,434 | 4,389 |
| Accumulated depreciation | $(1,573)$ | $(2,070)$ |
| Leased assets, net | 2,860 | 2,318 |
| Construction in progress | 315 | 1,484 |
| Other | 1,273 | 1,358 |
| Accumulated depreciation | $(1,052)$ | $(1,126)$ |
| Other, net | 220 | 232 |
| Total property, plant and equipment | 11,700 | 11,718 |
| Intangible assets |  |  |
| Goodwill | 1,764 | 1,494 |
| Other | 455 | 1,805 |
| Total intangible assets | 2,220 | 3,300 |
| Investments and other assets |  |  |
| Investment securities | 60 | 7,342 |
| Long-term advance payments | 2,320 | 2,308 |
| Deferred tax assets | 1,027 | 1,288 |
| Other | 861 | 858 |
| Total investments and other assets | 4,269 | 11,798 |
| Total non-current assets | 18,189 | 26,817 |
| Total assets | 53,117 | 60,737 |

Liabilities
Current liabilities

| Notes and accounts payable - trade | 6,746 | 4,813 |
| :--- | ---: | ---: |
| Current portion of long-term loans payable | - | 2,840 |
| Lease obligations | 537 | 530 |
| Income taxes payable | 373 | 492 |
| Provision for bonuses | 1,161 | 856 |
| Provision for bonuses for directors (and other officers) | 14 | 7 |
| Provision for sales returns | 17 | 22 |
| Other | 2,695 | 2,448 |
| Total current liabilities | 11,546 | 12,012 |
| n-current liabilities | 2,000 | 5,530 |
| Long-term loans payable | 2,534 | 2,014 |
| Lease obligations | 1,210 | 1,396 |
| Retirement benefit liability | 475 | 418 |
| Other |  | 6,220 |
| Total non-current liabilities |  | 17,767 |
| nyl liabilities |  | 2,360 |

Net assets
Shareholders' equity
Capital stock

| 3,799 | 3,799 |
| ---: | ---: |
| 5,023 | 5,841 |
| 27,119 | 29,243 |
| $(1,504)$ | $(78)$ |
| 34,438 | 38,804 |

Accumulated other comprehensive income
Valuation difference on available-for-sale securities

| 9 | $(340)$ |
| ---: | ---: |
| 23 | - |
| 850 | 896 |
| 27 | $(0)$ |
| 909 | 556 |
| 2 | 2 |
| 35,350 | 39,363 |
| 53,117 | 60,737 |

## Consolidated statements of income and consolidated statements of comprehensive income Consolidated statements of income

|  | (Millions of |  |
| :---: | :---: | :---: |
|  | Fiscal year ended <br> September 30, 2018 | Fiscal year ended <br> September 30, 2019 |
| Net sales | 37,909 | 36,279 |
| Cost of sales | 21,959 | 20,483 |
| Gross profit | 15,950 | 15,796 |
| Selling, general and administrative expenses |  |  |
| Sales commission | 1,819 | 1,888 |
| Salaries and bonuses | 2,560 | 2,572 |
| Provision for bonuses | 688 | 473 |
| Provision for bonuses for directors (and other officers) | 14 | 8 |
| Retirement benefit expenses | 148 | 156 |
| Research and development expenses | 1,760 | 2,052 |
| Depreciation | 470 | 334 |
| Amortization of goodwill | 275 | 279 |
| Other | 3,821 | 3,856 |
| Total selling, general and administrative expenses | 11,559 | 11,622 |
| Operating profit | 4,391 | 4,173 |
| Non-operating income |  |  |
| Foreign exchange gains | 24 | - |
| Dividend income of life insurance | 1 | 6 |
| Compensation income | 12 | 8 |
| Subsidy income | 39 | 0 |
| Insurance income | 11 | 116 |
| Other | 47 | 24 |
| Total non-operating income | 137 | 156 |
| Non-operating expenses |  |  |
| Interest expenses | 38 | 41 |
| Sales discounts | 12 | 6 |
| Foreign exchange losses | - | 108 |
| Other | 5 | 4 |
| Total non-operating expenses | 55 | 160 |
| Ordinary profit | 4,472 | 4,169 |
| Extraordinary income |  |  |
| Gain on sales of non-current assets | 5 | 4 |
| Total extraordinary income | 5 | 4 |
| Extraordinary losses |  |  |
| Loss on sales of non-current assets | 0 | 0 |
| Loss on retirement of non-current assets | 5 | 18 |
| Impairment loss | - | 193 |
| Total extraordinary losses | 5 | 212 |
| Profit before income taxes | 4,472 | 3,961 |
| Income taxes - current | 1,124 | 1,083 |
| Income taxes - deferred | (25) | (85) |
| Total income taxes | 1,099 | 998 |
| Profit | 3,372 | 2,962 |
| Profit attributable to non-controlling interests | 0 | 0 |
| Profit attributable to owners of parent | 3,372 | 2,962 |

Consolidated statements of comprehensive income

|  | (Millions of yen) |  |
| :---: | :---: | :---: |
|  | Fiscal year ended September 30, 2018 | Fiscal year ended September 30, 2019 |
| Profit | 3,372 | 2,962 |
| Other comprehensive income |  |  |
| Valuation difference on available-for-sale securities | 0 | (349) |
| Deferred gains or losses on hedges | 15 | (23) |
| Foreign currency translation adjustment | 172 | 45 |
| Remeasurements of defined benefit plans, net of tax | 10 | (27) |
| Total other comprehensive income | 198 | (353) |
| Comprehensive income | 3,571 | 2,609 |
| Comprehensive income attributable to |  |  |
| Comprehensive income attributable to owners of parent | 3,570 | 2,609 |
| Comprehensive income attributable to non-controlling interests | 0 | 0 |

## Consolidated statements of changes in equity

Fiscal year ended September 30, 2018

| (Millions of ye |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Shareholders' equity |  |  |  |  |
|  | Capital stock | Capital surplus | Retained earnings | Treasury shares | Total shareholders' equity |
| Balance at beginning of current period | 3,799 | 5,023 | 24,541 | $(1,476)$ | 31,887 |
| Changes of items during period |  |  |  |  |  |
| Dividends of surplus |  |  | (794) |  | (794) |
| Profit attributable to owners of parent |  |  | 3,372 |  | 3,372 |
| Purchase of treasury shares |  |  |  | (40) | (40) |
| Disposal of treasury shares |  |  |  | 12 | 12 |
| Net changes of items other than shareholders' equity |  |  |  |  |  |
| Total changes of items during period | - | - | 2,578 | (28) | 2,550 |
| Balance at end of current period | 3,799 | 5,023 | 27,119 | $(1,504)$ | 34,438 |



Fiscal year ended September 30, 2019

|  | (Millions of yen) |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | :---: |
|  | Capital stock | Capital surplus | Retained earnings | Treasury shares | Total shareholders' <br> equity |
|  |  | 3,799 |  | 5,023 |  |


|  | Accumulated other comprehensive income |  |  |  |  | Noncontrolling interests | Total net assets |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Valuation difference on available-forsale securities | Deferred gains or losses on hedges | Foreign currency translation adjustment | Remeasurements of defined benefit plans | Total accumulated other comprehensive income |  |  |
| Balance at beginning of current period | 9 | 23 | 850 | 27 | 909 | 2 | 35,350 |
| Changes of items during period |  |  |  |  |  |  |  |
| Dividends of surplus |  |  |  |  |  |  | (839) |
| Profit attributable to owners of parent |  |  |  |  |  |  | 2,962 |
| Purchase of treasury shares |  |  |  |  |  |  | (0) |
| Disposal of treasury shares |  |  |  |  |  |  | 2,243 |
| Net changes of items other than shareholders' equity | (349) | (23) | 45 | (27) | (353) | 0 | (353) |
| Total changes of items during period | (349) | (23) | 45 | (27) | (353) | 0 | 4,013 |
| Balance at end of current period | (340) | - | 896 | (0) | 556 | 2 | 39,363 |

Consolidated statements of cash flows

|  | (Millions of yen) |  |
| :---: | :---: | :---: |
|  | Fiscal year ended September 30, 2018 | Fiscal year ended September 30, 2019 |
| Cash flows from operating activities |  |  |
| Profit before income taxes | 4,472 | 3,961 |
| Depreciation | 1,976 | 1,850 |
| Impairment loss | - | 193 |
| Amortization of goodwill | 275 | 279 |
| Increase (decrease) in allowance for doubtful accounts | 0 | (6) |
| Increase (decrease) in provision for bonuses | 286 | (305) |
| Increase (decrease) in provision for bonuses for directors (and other officers) | 4 | (6) |
| Increase (decrease) in retirement benefit liability | 108 | 156 |
| Interest and dividend income | (2) | (3) |
| Interest expenses | 38 | 41 |
| Foreign exchange losses (gains) | (9) | 97 |
| Loss on retirement of non-current assets | 5 | 18 |
| Decrease (increase) in notes and accounts receivable - trade | $(1,731)$ | 3,965 |
| Decrease (increase) in inventories | 235 | 581 |
| Increase (decrease) in notes and accounts payable - trade | 994 | $(1,937)$ |
| Decrease (increase) in long-term advance payments | (968) | (16) |
| Insurance income | (11) | (116) |
| Other, net | (46) | (828) |
| Subtotal | 5,628 | 7,925 |
| Interest and dividend income received | 2 | 3 |
| Proceeds from insurance income | 11 | 116 |
| Interest expenses paid | (70) | (53) |
| Income taxes paid | $(1,797)$ | (957) |
| Net cash provided by (used in) operating activities | 3,773 | 7,035 |
| Cash flows from investing activities |  |  |
| Purchase of investment securities | - | $(7,786)$ |
| Purchase of property, plant and equipment | $(1,446)$ | $(1,701)$ |
| Proceeds from sales of property, plant and equipment | 1,283 | 4 |
| Purchase of intangible assets | (184) | $(1,583)$ |
| Decrease (increase) in long-term advance payments | (59) | (955) |
| Subsidy income | 9 | - |
| Payments for guarantee deposits | (674) | - |
| Other, net | (1) | (1) |
| Net cash provided by (used in) investing activities | $(1,073)$ | $(12,024)$ |
| Cash flows from financing activities |  |  |
| Proceeds from sales of treasury shares | - | 2,225 |
| Purchase of treasury shares | (40) | (0) |
| Proceeds from long-term loans payable | - | 7,000 |
| Repayments of long-term loans payable | (653) | (630) |
| Cash dividends paid | (794) | (839) |
| Repayments of lease obligations | (513) | (490) |
| Net cash provided by (used in) financing activities | $(2,001)$ | 7,265 |
| Effect of exchange rate change on cash and cash equivalents | 49 | (32) |
| Net increase (decrease) in cash and cash equivalents | 747 | 2,243 |
| Cash and cash equivalents at beginning of period | 5,503 | 6,251 |
| Cash and cash equivalents at end of period | 6,251 | 8,494 |

